A Phase 1, Randomized, Double-blind, Placebo Controlled, Single-center, Single Dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of CDP6038 Administered Subcutaneously to Healthy Japanese Males
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2014
At a glance
- Drugs Olokizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors UCB
- 26 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 Sep 2011 Actual end date Sep 2011 added as reported by ClinicalTrials.gov.
- 19 Aug 2011 Planned End Date changed from 1 Aug 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.